Advertisement

Topics

ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes

03:21 EDT 2 Aug 2018 | RTTNews

Today's Daily Dose brings you news about BioCryst Pharma's stock offering; AxoGen and Blueprint Medicines' strong Q2 financial results; positive results of RXi Pharmaceuticals' phase I/II trial with RXI-109 for retinal scarring and reverse stock split of Synthetic Biologics.

Original Article: ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes

NEXT ARTICLE

More From BioPortfolio on "ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...